Decreased diabetes risk over 9 year after 18-month oral l-arginine treatment in middle-aged subjects with impaired glucose tolerance and metabolic syndrome (extension evaluation of...

por Monti, Lucilla D., Galluccio, Elena, Villa, Valentina, Fontana, Barbara, Spadoni, Serena, Piatti, Pier Marco
Publicado 2017

Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes...

por Rosenstock, Julio, Aronson, Ronnie, Grunberger, George, Hanefeld, Markolf, Piatti, PierMarco, Serusclat, Pierre, Cheng, Xi, Zhou, Tianyue, Niemoeller, Elisabeth, Souhami, Elisabeth, Davies, Melanie
Publicado 2017